list glp 1 receptor agonist Holding GLP-1 Agonists Prior to Elective Procedures Trends in the Development of

As healthcare systems prioritize chronic disease management, GLP-1 receptor agonists are positioned to remain a critical component of treatment protocols

Buchan AM, Polak JM, Capella C, Solcia E, Pearse AG

Current opinion on prucalopride in gastroparesis and chronic constipation treatment: a focus on patient selection and safety

Evidence suggests that IBD pathogenesis is closely linked to gut failure in controlling inflammation, with enteroendocrine cells (EECs) playing a pivotal role in the process (91)

A number of other manufacturers are developing dual- and tri-agonists (e.g., Amgen, Carmot, Zealand), setting the stage for a competitive market

Subgroup analyses (Figure 5) (exploratory) revealed similar directional trends across subgroups, including patients with organ transplantation (HR 0.27, 95% CI 0.090.82